Current location: Home > News > Company news
Arctic Vision’s Innovative Suprachoroidal Space Microinjection Treatment Benefits Patients with Uveitis Macular Edema
2022-09-23

In September, Arctic Vision worked with Dr. Nicholas Fung Siu Kay, leading clinical ophthalmologist at the University of Hong Kong Eye Center, to conduct the first-ever suprachoroidal space (SCS®) microinjection treatment for patients with macular edema uveitis. This marks the first real-world application of this groundbreaking therapy outside of the United States. The momentous milestone for Arctic Vision was covered in a report by top-tier Hong Kong media


18a1c5cc684b54f74c10d3bc815646e.png


ADDRESS
@1Suite 906-908, 9F, Tower II, Century Link, 1196 Century Avenue, Shanghai, China @2Suite A09, 10th Floor, Twin Towers (East), B 12 Jianguomenwai Avenue, Beijing, China @3Suite 2305, 23/F, The Gateway Prudential Tower, Harbour City, No 21 Canton Road, Tsim Sha Tsui, Kowloon, Hong Kong @4Suite Level 5 63 Pirie Street, Adelaide, SA 5000, Australia
SUBSCRIBE TO OUR NEWSLETTER
Subscribe

To report a potential adverse event, please refer to the contact information below:

Global: globalsafety@arcticvision.com

Mainland China: safety.cn@arcticvision.com

Hong Kong, China: safety.hk@arcticvision.com

Copyright © 2023 ARCTIC VISION HONG KONG BIOTECH LIMITED